Oruka Therapeutics Announces Upcoming Investor Conferences
Oruka Therapeutics, Inc. (Nasdaq: ORKA), a progressive biotechnology firm based in Menlo Park, California, is gearing up to showcase its innovative approaches to treating chronic skin diseases at several important investor conferences this November. Renowned for its commitment to improving patient outcomes, Oruka is eager to share its advancements, particularly in the treatment of plaque psoriasis, through valuable presentations.
Conference Details
Oruka will be participating in the following prestigious investor events to connect with stakeholders and share insights into its groundbreaking research:
Stifel 2024 Healthcare Conference
Date: Monday, November 18
Time: 2:25 PM ET
Jefferies London Healthcare Conference
Date: Wednesday, November 20
Time: 2:00 PM GMT
For those unable to attend, Oruka will also provide a webcast and replay of its presentations on their investor events website, ensuring that interested parties can catch up on the crucial developments shared during these conferences.
About Oruka Therapeutics
Oruka Therapeutics is at the forefront of developing novel biologics aimed at transforming the way chronic skin diseases are treated. The company's mission reflects a deep commitment to enhancing the lives of patients suffering from conditions like plaque psoriasis, striving to achieve optimal health outcomes. Oruka's focus is on creating high-efficacy treatments that can free patients from their condition with minimal dosing frequency, potentially as little as once or twice a year.
Backed by a proprietary portfolio of advanced antibody therapies engineered in collaboration with Paragon Therapeutics, Oruka targets the fundamental mechanisms of plaque psoriasis and related dermatologic and inflammatory diseases. This strategic focus positions the company to deliver potentially best-in-class solutions, setting a new benchmark in patient care.
Investors and Stakeholder Engagement
Oruka recognizes that open communication with investors is essential for fruitful relationships. By engaging in these conferences, Oruka aims to not only inform but also foster dialogue with current and potential investors regarding its vision and strategy moving forward in the biopharmaceutical landscape.
Your Next Steps with Oruka
Investors interested in learning more about Oruka Therapeutics’ innovative approaches are encouraged to visit www.orukatx.com for additional information about their pipeline and ongoing research initiatives. Additionally, Oruka is active on LinkedIn, where stakeholders can follow updates about the company and its milestones.
Investor Contact Information
For further inquiries, investors can connect with Alan Lada by phone at (650)-606-7911 or via email at alan.lada@orukatx.com. Oruka is dedicated to providing timely and transparent communication as it progresses.
Frequently Asked Questions
What is Oruka Therapeutics known for?
Oruka Therapeutics specializes in developing innovative biologics for the treatment of chronic skin diseases, particularly plaque psoriasis.
When are the upcoming investor conferences for Oruka?
Oruka will present at the Stifel 2024 Healthcare Conference on November 18 and at the Jefferies London Healthcare Conference on November 20.
How can I access Oruka's presentations?
You can access webcasts and replays of Oruka's presentations on their investor events website.
Who can I contact for investor inquiries?
For investor inquiries, you can contact Alan Lada at (650)-606-7911 or email him at alan.lada@orukatx.com.
Where can I find more information about Oruka's products?
For detailed information about Oruka's pipeline and product offerings, visit their official website at www.orukatx.com.